BGB C354
Alternative Names: BGB-C354Latest Information Update: 28 Aug 2024
At a glance
- Originator BeiGene
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Jul 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Australia, USA (IV) (NCT06422520)
- 05 Jul 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia, USA (IV) (NCT06422520)
- 21 May 2024 BeiGene plans a phase I trial for Solid tumours (Late-stage disease, Combination therapy, Monotherapy, Metastatic disease, Inoperable/Unresectable) (IV) in June 2024 (NCT06422520)